1. Academic Validation
  2. YM-254890 analogues, novel cyclic depsipeptides with Galpha(q/11) inhibitory activity from Chromobacterium sp. QS3666

YM-254890 analogues, novel cyclic depsipeptides with Galpha(q/11) inhibitory activity from Chromobacterium sp. QS3666

  • Bioorg Med Chem. 2004 Jun 15;12(12):3125-33. doi: 10.1016/j.bmc.2004.04.006.
Masatoshi Taniguchi 1 Ken-Ichi Suzumura Koji Nagai Tomihisa Kawasaki Jun Takasaki Mitsuhiro Sekiguchi Yumiko Moritani Tetsu Saito Kazumi Hayashi Shigeo Fujita Shin-Ichi Tsukamoto Ken-Ichi Suzuki
Affiliations

Affiliation

  • 1 Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd, 21, Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. [email protected]
Abstract

The structure elucidation and biological activity of novel YM-254890 (1) analogues and semi-synthetic derivatives are described. Three natural analogues, YM-254891 (2), YM-254892 (3), and YM-280193 (4), were isolated from the fermentation broth of Chromobacterium sp. QS3666, and two hydrogenated derivatives, YM-385780 (5) and YM-385781 (6), were synthesized from YM-254890. Their structures were determined by one- and two-dimensional NMR studies and mass spectrometry. Among these compounds, two natural analogues 2-3 which possessed acyl groups at beta-HyLeu-1 and one derivative 6 whose conformation was similar to that of 1 showed comparable Galpha(q/11) inhibitory activity to that of 1. This indicates that the acyl beta-HyLeu residue plays an important role in activity and also that the alpha,beta-unsaturated carbonyl group of the N-MeDha residue is not critical to activity. The Other hydrogenated derivative 5 had significantly less activity, which could be attributed to conformational differences.

Figures
Products